{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:17:01Z","timestamp":1792513021559,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disease caused by mutations in the ADA2 gene. DADA2 has a broad spectrum of clinical presentations. Apart from systemic manifestations, we can categorize most of the signs and symptoms of DADA2 into the three groups of vasculitis, hematologic abnormalities, and immunologic dysregulations. The most dominant vasculitis features are skin manifestations, mostly in the form of livedo racemosa\/reticularis, and early onset ischemic or hemorrhagic strokes. Hypogammaglobulinemia that is found in many cases of DADA2 brings immunodeficiencies into the differential diagnosis. Cytopenia, pure red cell aplasia (PRCA), and bone marrow failure (BMF) are the hematologic abnormalities commonly found in DADA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We introduce eleven patients with DADA2 diagnosis, including two brothers and sisters, one set of twin sisters, and one father and his daughter and son. Ten patients (91%) had consanguineous parents. All the patients manifested livedo racemose\/reticularis. Ten patients (91%) reported febrile episodes, and seven (64%) had experienced strokes. Only one patient had hypertension. Two of the patients (11%) presented decreased immunoglobulin levels. One of the patients presented with PRCA. Except for the PRCA patient with G321E mutation, all of our patients delivered G47R mutation, the most common mutation in DADA2 patients. Except for one patient who unfortunately passed away before the diagnosis was made and proper treatment was initiated, the other patients\u2019 symptoms are currently controlled; two of the patients presented with mild symptoms and are now being treated with colchicine, and the eight others responded well to anti-TNFs. The PRCA patient still suffers from hematologic abnormalities and is a candidate for a bone marrow transplant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Considering the manifestations and the differential diagnoses, DADA2 is not merely a rheumatologic disease, and introducing this disease to hematologists, neurologists, and immunologists is mandatory to initiate prompt and proper treatment. The efficacy of anti-TNFs in resolving the symptoms of DADA2 patients have been proven, but not for those with hematologic manifestations. Similarly, they were effective in controlling the symptoms of our cohort of patients, except for the one patient with cytopenia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-023-00838-3","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T13:02:32Z","timestamp":1686661352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A case series of ten plus one deficiency of adenosine deaminase 2 (DADA2) patients in Iran"],"prefix":"10.1186","volume":"21","author":[{"given":"Kosar","family":"Asna Ashari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Aslani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Parvaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheleh","family":"Assari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Tahghighi Sharabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ronagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Shahrooei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Moafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4648-3573","authenticated-orcid":false,"given":"Vahid","family":"Ziaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"issue":"10","key":"838_CR1","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1307361","volume":"370","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"838_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1042\/BJ20050683","volume":"391","author":"AV Zavialov","year":"2005","unstructured":"Zavialov AV, Engstr\u00f6m \u00c3. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J. 2005;391(1):51\u20137.","journal-title":"Biochem J"},{"issue":"3","key":"838_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00018-016-2357-0","volume":"74","author":"Y Kaljas","year":"2017","unstructured":"Kaljas Y, Liu C, Skaldin M, Wu C, Zhou Q, Lu Y, et al. Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells. Cell Mol Life Sci. 2017;74(3):555\u201370.","journal-title":"Cell Mol Life Sci"},{"issue":"16","key":"838_CR4","doi-asserted-by":"publisher","first-page":"12367","DOI":"10.1074\/jbc.M109.083527","volume":"285","author":"AV Zavialov","year":"2010","unstructured":"Zavialov AV, Yu X, Spillmann D, Lauvau G, Zavialov AV. Structural basis for the growth factor activity of human adenosine deaminase ADA2*\u2666. J Biol Chem. 2010;285(16):12367\u201377.","journal-title":"J Biol Chem"},{"issue":"2","key":"838_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1189\/jlb.1109764","volume":"88","author":"AV Zavialov","year":"2010","unstructured":"Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol. 2010;88(2):279\u201390.","journal-title":"J Leukoc Biol"},{"key":"838_CR6","doi-asserted-by":"publisher","first-page":"935957","DOI":"10.3389\/fimmu.2022.935957","volume":"13","author":"S Signa","year":"2022","unstructured":"Signa S, Bertoni A, Penco F, Caorsi R, Cafaro A, Cangemi G, et al. Adenosine Deaminase 2 Deficiency (DADA2): a crosstalk between innate and adaptive immunity. Front Immunol. 2022;13:935957.","journal-title":"Front Immunol"},{"issue":"11","key":"838_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-017-0699-8","volume":"19","author":"H Hashem","year":"2017","unstructured":"Hashem H, Kelly SJ, Ganson NJ, Hershfield MS. Deficiency of adenosine deaminase 2 (DADA2), an inherited cause of polyarteritis nodosa and a mimic of other systemic rheumatologic disorders. Curr Rheumatol Rep. 2017;19(11):1\u20139.","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"838_CR8","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.jaci.2019.12.908","volume":"145","author":"PY Lee","year":"2020","unstructured":"Lee PY, Kellner ES, Huang Y, Furutani E, Huang Z, Bainter W, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol. 2020;145(6):1664\u201372e10.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"838_CR9","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3899\/jrheum.150024","volume":"42","author":"ED Batu","year":"2015","unstructured":"Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M, et al. A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations. J Rhuematol. 2015;42(8):1532\u20134.","journal-title":"J Rhuematol"},{"issue":"1","key":"838_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3899\/jrheum.181384","volume":"47","author":"S \u00d6zen","year":"2020","unstructured":"\u00d6zen S, Batu ED, Ta\u015fk\u0131ran EZ, \u00d6zkara HA, \u00dcnal \u015e, G\u00fcleray N, et al. A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2. J Rhuematol. 2020;47(1):117\u201325.","journal-title":"J Rhuematol"},{"issue":"1","key":"838_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-017-0193-x","volume":"15","author":"A Skrabl-Baumgartner","year":"2017","unstructured":"Skrabl-Baumgartner A, Plecko B, Schmidt WM, K\u00f6nig N, Hershfield M, Gruber-Sedlmayr U, et al. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. Pediatr Rheumatol. 2017;15(1):1\u20135.","journal-title":"Pediatr Rheumatol"},{"key":"838_CR12","unstructured":"Aksentijevich I, Barron K. Adenosine deaminase 2 deficiency. 2019."},{"issue":"1","key":"838_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-016-0111-7","volume":"14","author":"R Caorsi","year":"2016","unstructured":"Caorsi R, Penco F, Schena F, Gattorno M. Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol. 2016;14(1):1\u201316.","journal-title":"Pediatr Rheumatol"},{"issue":"4","key":"838_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.revmed.2017.11.006","volume":"39","author":"A Fayand","year":"2018","unstructured":"Fayand A, Sarrabay G, Belot A, Hentgen V, Kone-Paut I, Grateau G, et al. Les multiples facettes du d\u00e9ficit en ADA2, vascularite, maladie auto-inflammatoire et immunod\u00e9ficit: mise au point \u00e0 partir des 135 cas de la litt\u00e9rature. La Revue de M\u00e9decine Interne. 2018;39(4):297\u2013306.","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"838_CR15","doi-asserted-by":"crossref","unstructured":"Lee PY, Kellner ES, Huang Y, Furutani E, Huang Z, Bainter W et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). Journal of allergy and clinical immunology. 2020;145(6):1664-72. e10.","DOI":"10.1016\/j.jaci.2019.12.908"},{"key":"838_CR16","doi-asserted-by":"publisher","first-page":"811473","DOI":"10.3389\/fimmu.2021.811473","volume":"12","author":"KS Barron","year":"2021","unstructured":"Barron KS, Aksentijevich I, Deuitch NT, Stone DL, Hoffmann P, Videgar-Laird R, et al. The spectrum of the Deficiency of Adenosine Deaminase 2: an observational analysis of a 60 patient cohort. Front Immunol. 2021;12:811473.","journal-title":"Front Immunol"},{"issue":"2","key":"838_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10875-018-0480-4","volume":"38","author":"TF Michniacki","year":"2018","unstructured":"Michniacki TF, Hannibal M, Ross CW, Frame DG, DuVall AS, Khoriaty R, et al. Hematologic Manifestations of Deficiency of Adenosine Deaminase 2 (DADA2) and response to tumor necrosis factor inhibition in DADA2-Associated Bone Marrow failure. J Clin Immunol. 2018;38(2):166\u201373.","journal-title":"J Clin Immunol"},{"issue":"3","key":"838_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10875-016-0245-x","volume":"36","author":"J Schepp","year":"2016","unstructured":"Schepp J, Bulashevska A, Mannhardt-Laakmann W, Cao H, Yang F, Seidl M, et al. Deficiency of adenosine deaminase 2 causes antibody deficiency. J Clin Immunol. 2016;36(3):179\u201386.","journal-title":"J Clin Immunol"},{"issue":"5","key":"838_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10875-018-0525-8","volume":"38","author":"I Meyts","year":"2018","unstructured":"Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38(5):569\u201378.","journal-title":"J Clin Immunol"},{"issue":"24","key":"838_CR20","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1182\/blood-2017-07-798660","volume":"130","author":"H Hashem","year":"2017","unstructured":"Hashem H, Kumar AR, M\u00fcller I, Babor F, Bredius R, Dalal J, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood. 2017;130(24):2682\u20138.","journal-title":"Blood"},{"issue":"10","key":"838_CR21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1056\/NEJMoa1307362","volume":"370","author":"P Navon Elkan","year":"2014","unstructured":"Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921\u201331.","journal-title":"N Engl J Med"},{"issue":"5","key":"838_CR22","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/rheumatology\/kev439","volume":"55","author":"JM Van Montfrans","year":"2016","unstructured":"Van Montfrans JM, Hartman EA, Braun KP, Hennekam EA, Hak EA, Nederkoorn PJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology. 2016;55(5):902\u201310.","journal-title":"Rheumatology"},{"issue":"16","key":"838_CR23","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1182\/bloodadvances.2020003811","volume":"5","author":"M Zoccolillo","year":"2021","unstructured":"Zoccolillo M, Brigida I, Barzaghi F, Scala S, Hern\u00e1ndez RJ, Basso-Ricci L, et al. Lentiviral correction of enzymatic activity restrains macrophage inflammation in adenosine deaminase 2 deficiency. Blood Adv. 2021;5(16):3174\u201387.","journal-title":"Blood Adv"},{"key":"838_CR24","doi-asserted-by":"crossref","unstructured":"Hong Y, Casimir M, Houghton BC, Zhang F, Jensen B, Omoyinmi E et al. Lentiviral mediated ADA2 gene transfer corrects the defects Associated with Deficiency of Adenosine Deaminase Type 2. Front Immunol. 2022;13.","DOI":"10.3389\/fimmu.2022.852830"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00838-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00838-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00838-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T13:02:39Z","timestamp":1686661359000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00838-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["838"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00838-3","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical committee of Tehran University of Medical Sciences approved this study. Written consent was obtained from the parents of patients for participating their children in this report of the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained from the parents of patients for publishing this report of the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}